Search Result

Results for "

advanced glycation end-products

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aldose Reductase (5) Amyloid-β (5) Apoptosis (1) Biochemical Assay Reagents (1) Cathepsin (1) Dipeptidyl Peptidase (2) Endogenous Metabolite (7) GABA Receptor (2) GLP Receptor (1) Interleukin Related (1) Keap1-Nrf2 (1) Reactive Oxygen Species (2) Serotonin Transporter (1) TNF Receptor (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (7) Cardiovascular Disease (4) Infection (1) Inflammation/Immunology (9) Metabolic Disease (20) Neurological Disease (8)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106024B

Alagebrium chloride 1 Publications Verification ALT711	Endogenous Metabolite	Metabolic Disease
Alagebrium chloride (ALT711) is an **advanced glycation end product (AGE**) inhibitor.

HY-114883A

Homocarnosine TFA L-Homocarnosine TFA; γ-Aminobutyryl-L-histidine TFA	GABA Receptor Endogenous Metabolite	Neurological Disease
Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .

HY-N4089

Quercetin 3-gentiobioside	Aldose Reductase	Metabolic Disease
Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs) .

HY-B1745

Pyridoxylamine 2 Publications Verification	Endogenous Metabolite	Metabolic Disease
Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.

HY-B1745A

Pyridoxylamine dihydrochloride 2 Publications Verification	Endogenous Metabolite	Metabolic Disease
Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .

HY-W286743

Nε-(Carboxymethyl)-L-lysine CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine	Biochemical Assay Reagents	Cardiovascular Disease Metabolic Disease Cancer
Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

HY-N7426

3-Deoxyglucosone 3-Deoxy-D-glucosone	GLP Receptor	Metabolic Disease
3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes .

HY-N7069

4-Isopropylbenzyl alcohol	Others	Cancer
4-Isopropylbenzyl alcohol is a chemical composition of the essential oils from the leaves and flowers of Camellia nitidissima. C. nitidissima possess multiple biological activities including antioxidant activity, anticancer activity, and cytotoxicity as well as inhibiting the formation of advanced glycation end-products .

HY-114883

Homocarnosine L-Homocarnosine; γ-Aminobutyryl-L-histidine	GABA Receptor Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects .Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .

HY-131528

Tenilsetam CAS 997	Others	Neurological Disease Metabolic Disease
Tenilsetam (CAS 997) is an antidementia compound. Tenilsetam is an advanced glycation end product (AGE) inhibitor. Tenilsetam inhibits early retinopathy in experimental diabetes rats .

HY-N4089R

Quercetin 3-gentiobioside (Standard)	Aldose Reductase	Metabolic Disease
Quercetin 3-gentiobioside (Standard) is the analytical standard of Quercetin 3-gentiobioside. This product is intended for research and analytical applications. Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs) .

HY-76383

LR-90	Others	Metabolic Disease Inflammation/Immunology
LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .

HY-N7628

Cassiaside C Toralactone 9-O-β-D-gentiobioside	Endogenous Metabolite	Metabolic Disease
Cassiaside C (Toralactone 9-O-β-D-gentiobioside) is a naphthopyrone isolated from the seed of Cassia tora and has inhibitory activity on advanced glycation end products (AGE) formation in vitro .

HY-N6883

6-Methoxytricin	Aldose Reductase	Metabolic Disease
6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC₅₀ values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent .

HY-B1745AR

Pyridoxylamine dihydrochloride (Standard)	Endogenous Metabolite	Metabolic Disease
Pyridoxylamine (dihydrochloride) (Standard) is the analytical standard of Pyridoxylamine (dihydrochloride). This product is intended for research and analytical applications. Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .

HY-N12071

Lucidin-ω-Me ether	Others	Others
Lucidin-ω-Me ether (Compound 2) can be isolated from the roots of Knoxia valerianoides. Lucidin-ω-Me ether inhibits the advanced glycation end products (AGEs) formation in vitro(IC₅₀: 62.79 μM) .

HY-14892

Gemigliptin LC15-0444	Dipeptidyl Peptidase	Metabolic Disease Cancer
Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-N8375

Sieboldin	Others	Metabolic Disease
Sieboldin is a dihydrochalcone, which inhibits the production of advanced glycation end products (AGE) produced by bovine serum albumins (BSA), has free radical scavenging activity and cytotoxicity in cancer cell lines, and is also used to capture of methylglyoxal (MGO) from Malus baccata .

HY-14892A

Gemigliptin tartrate LC15-0444 tartrate	Dipeptidyl Peptidase	Metabolic Disease
Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC₅₀ of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .

HY-141537

ABR-238901 4 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research .

HY-50682

Azeliragon Maximum Cited Publications 10 Publications Verification TTP488; PF-04494700	Amyloid-β	Neurological Disease
Azeliragon (TTP488) is an orally bioavailable inhibitor of the *receptor for advanced* glycation end products (RAGE)** in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-50682A

Azeliragon dihydrochloride TTP488 dihydrochloride; PF-04494700 dihydrochloride	Amyloid-β	Neurological Disease Cancer
Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the *receptor for advanced* glycation end products (RAGE)** in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB) .

HY-N0033

Poliumoside 2 Publications Verification	Aldose Reductase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC₅₀s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity .

HY-P2268

RAGE antagonist peptide 2 Publications Verification	Amyloid-β	Inflammation/Immunology Cancer
RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities .

HY-P2268A

RAGE antagonist peptide TFA 2 Publications Verification	Amyloid-β	Inflammation/Immunology Cancer
RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities .

HY-113033

Pentosidine	Others	Neurological Disease Metabolic Disease
Pentosidine is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .

HY-N4170

Chebulic acid 1 Publications Verification	Keap1-Nrf2 Reactive Oxygen Species	Metabolic Disease
Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection .

HY-113033A

Pentosidine TFA	Others	Neurological Disease Metabolic Disease
Pentosidine TFA is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine TFA is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .

HY-N0033R

Poliumoside (Standard)	Aldose Reductase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Poliumoside (Standard) is the analytical standard of Poliumoside. This product is intended for research and analytical applications. Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC₅₀s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity .

HY-129611

Bromelain	Apoptosis	Inflammation/Immunology Cancer
Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .

HY-146619

RAGE/SERT-IN-1	Amyloid-β Serotonin Transporter	Neurological Disease
RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC₅₀s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ_25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression .

HY-124750

NecroX-7	TNF Receptor Interleukin Related Toll-like Receptor (TLR) Reactive Oxygen Species	Cardiovascular Disease Inflammation/Immunology
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research .

HY-P0109

(S,S)-Z-FA-FMK	Cathepsin	Others
(S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position .

HY-106024A

Alagebrium bromide ALT711 bromide	Others	Infection
Alagebrium bromide is a cross-link breaker. This study investigated the role of advanced glycation end products (AGEs) in mediating protein kinase C (PKC) isoform expression in diabetic nephropathy. In vitro, vascular smooth muscle cells cultured in high glucose (25-mmol/l) showed increased translocation and expression of PKC-α compared with cells cultured in low glucose (5-mmol/l). Coculture with ALT-711 more effectively attenuated the increased expression and translocation of PKC-α compared with aminoguanidine, an inhibitor of AGE formation. Streptozotocin-induced diabetic rats were randomized to no treatment, ALT-711 treatment, or aminoguanidine treatment. Diabetes induced an increase in PKC-α as well as -βI, -βII, and -ε isoforms. ALT-711 and aminoguanidine treatment, both of which attenuated renal AGE accumulation, abolished these increases in PKC expression. However, only ALT-711 reduced the translocation of phosphorylated PKC-α from the cytoplasm to the membrane. ALT-711 treatment attenuated the expression of vascular endothelial growth factor (VEGF) and extracellular matrix proteins (fibronectin and laminin) and was associated with a reduction in albuminuria. Aminoguanidine had no effect on VEGF expression, although a reduction in fibronectin and laminin was observed. These findings suggest that AGEs are important stimulators of PKC activation, particularly PKC-α, in patients with diabetic nephropathy, which can be directly inhibited by ALT-711.

Cat. No.	Product Name	Type

HY-W286743

Nε-(Carboxymethyl)-L-lysine CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine	Biochemical Assay Reagents
Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

Nε-(Carboxymethyl)-L-lysine

CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine

Biochemical Assay Reagents

Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer .

Cat. No.	Product Name	Target	Research Area

HY-P2268

RAGE antagonist peptide 2 Publications Verification	Amyloid-β	Inflammation/Immunology Cancer
RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities .

HY-P2268A

RAGE antagonist peptide TFA 2 Publications Verification	Amyloid-β	Inflammation/Immunology Cancer
RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities .

HY-P0109

(S,S)-Z-FA-FMK	Cathepsin	Others
(S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position .

Alagebrium chloride 1 Publications Verification ALT711	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Alagebrium chloride (ALT711) is an **advanced glycation end product (AGE**) inhibitor.

Homocarnosine TFA L-Homocarnosine TFA; γ-Aminobutyryl-L-histidine TFA	Structural Classification Natural Products Neurological Disease Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	GABA Receptor Endogenous Metabolite
Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .

Quercetin 3-gentiobioside	Flavonols Structural Classification Flavonoids other families Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Disease Research Fields	Aldose Reductase
Quercetin 3-gentiobioside is isolated from A. iwayomogi, AR and AGE formation inhibitor, demonstrates biological activities against Aldose reductase (AR) and the formation of advanced glycation endproducts (AGEs) .

Pyridoxylamine 2 Publications Verification	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Disease markers Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.

Pyridoxylamine dihydrochloride 2 Publications Verification	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81086

	RAGE Antibody advanced glycosylation end product specific receptor; advanced glycosylation end product-specific receptor; AGER; EC 2.7.11.22; LE 9211 A antigen; LE-9211-A antigen; MGC22357; MOK; RAGE 1; RAGE1; MOK protein kinase; Receptor for advanced glycation endproducts; Renal tumor antigen 1; Renal tumor antigen; Renal cell carcinoma antigen (MOK protein kinase); Renal tumor antigen 1; RAGE_HUMAN.	WB, IHC-P, FC	Human, Mouse, Rat,
	RAGE Antibody is an unconjugated, approximately 42 kDa, rabbit-derived, anti-RAGE polyclonal antibody. RAGE Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

advanced glycation end-products

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Antibodies

Natural
Products